Effects of microRNAs in hypertension disease

Year 2022, Volume: 8 Issue: 1, 131 - 138, 04.01.2022

Nuray Altıntaş , Onur Tonk , Özge Sarıca Yılmaz

https://doi.org/10.18621/eurj.855796

Abstract

Hypertension is a cardiovascular disease which is a very common hemodynamic syndrome, and it has different prevalence in different regions as it is common all over the world. In recent studies, it is known that microRNAs (miRNAs) play an important role in hypertension disease and that miRNA expressions are regulated by epigenetic mechanisms. There are also studies proving that microRNAs are new therapeutic targets for pulmonary arterial hypertension, and miRNAs can participate in the pathophysiology of hypertension in many ways and it can be used as a biomarker for hypertension disease. It is thought that miRNAs can be effective in the diagnosis and treatment of hypertension and further studies are needed. Recently, the relationship between miRNAs and hypoxia has also been focused on and has been taken into account in studies. In this review, we aimed to present the effects of miRNAs on hypertensive disease and current approaches. Finally, with gene targeting studies, we think that miRNAs, which can be biomarkers and molecular agents, will hold promise in preventing the progression of hypertension in the future, and we hope that they can create ideas for future studies.

Keywords

miRNA, Hypertension, Epigenetic

References

• 1. Wang Y, Jin L. miRNA-145 is associated with spontaneous hypertension by targeting SLC7A1. Exp Ther Med 2018;15:548-52.
• 2. Li X, Wei Y, Wang Z. microRNA-21 and hypertension. Hypertens Res 2018;41:649-61.
• 3. Wise IA, Charchar FJ. Epigenetic modifications in essential hypertension. Int J Mol Sci 2016;17:451.
• 4. Jalnapurkar S, Mangaonkar A, Mondal A, Burke J, Fulzele S, Kolhe R. MicroRNAs: as a novel potential tool for diagnosis, prognosis, and therapeutic agents in hypertension. Hypertens Cardiol 2015;1:14-22.
• 5. Liu H, Yin T, Yan W, Si R, Wang B, Chen M, et al. Dysregulation of microRNA-214 and PTEN contributes to the pathogenesis of hypoxic pulmonary hypertension. Int J Chron Obstruct Pulmon Dis 2017;12:1781-91.
• 6. Güzelgül F, Aksoy K. A gene expression regulator: miRNA. Arşiv Kaynak Tarama Dergisi 2015;24:472-93.
• 7. Zhou G, Chen T, Raj JU. MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2015;52:139-51.
• 8. Shomron N, Levy C. MicroRNA-biogenesis and pre-mRNA splicing crosstalk. J Biomed Biotechnol 2009;2009:594678.
• 9. Gibbons A, Udawela M, Dean B. Non-coding RNA as novel players in the pathophysiology of schizophrenia. Noncoding RNA 2018;4:11.
• 10. Beitzinger M, Meister G. Experimental identification of microRNA targets by immunoprecipitation of argonaute protein complexes. In: Dalmay T (eds). MicroRNAs in Development. Methods in Molecular Biology (Methods and Protocols). Humana Press. 2011.
• 11. Frydrych Capelari É, da Fonseca GC, Guzman F, Margis R. Circular and micro RNAs from arabidopsis thaliana flowers are simultaneously isolated from AGO-IP libraries. Plants (Basel) 2019;8:302.
• 12. Arif M, Sadayappan S, Becker RC, Martin LJ, Urbina EM. Epigenetic modification: a regulatory mechanism in essential hypertension. Hypertens Res 2019;42:1099-113.
• 13. Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol 2019;51:11-7.
• 14. Cheng X, Wang Y, Du L. Epigenetic modulation in the initiation and progression of pulmonary hypertension. Hypertension 2019;74:733-9.
• 15. Napoli C, Benincasa G, Loscalzo J. Epigenetic inheritance underlying pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2019;39:653-64.
• 16. Erkoç, Sultan Balız. Eskişehir Mahmudiye’de erişkinlerde hipertansiyon insidansı ve risk faktörleri. Halk Sağlığı Anabilim Dalı, Tıpta Uzmanlık Tezi, Eskişehir, 2013.
• 17. Watanabe K, Narumi T, Watanabe T, Otaki Y, Takahashi T, Aono T, et al. The association between microRNA-21 and hypertension-induced cardiac remodeling. PLoS One 2020;15:e0226053.
• 18. Miao R, Wang Y, Wan J, Leng D, Gong J, Li J, et al. Microarray analysis and detection of microRNAs associated with chronic thrombo embolic pulmonary hypertension. BioMed Res Int 2017;2017:8529796.
• 19. Nosalski R, Siedlinski M, Denby L, McGinnigle E, Nowak M, Cat AND, et al. T-cell-derived miRNA-214 mediates perivascular fibrosis in hypertension. Circ Res 2020;126:988-1003.
• 20. Qi H, Liu Z, Liu B, Cao H, Sun W, Yan Y, et al. micro-RNA screening and prediction model construction for diagnosis of salt-sensitive essential hypertension. Medicine (Baltimore) 2017;96:e6417.
• 21. Nandakumar P, Tin A, Grove ML, Ma J, Boerwinkle E, Coresh J, et al. MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension. PLoS One 2017;12:e0176734.
• 22. Dluzen DF, Kim Y, Bastian P, Zhang Y, Lehrmann E, Becker KG et al. MicroRNAs modulate oxidative stress in hypertension through PARP-1 regulation. Oxid Med Cell Longev 2017;2017:3984280.
• 23. Liu A, Liu Y, Li B, Yang M, Liu Y, Su J. Role of miR-223-3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway. Cell Prolif 2019;52:e12550.
• 24. Mondejar-Parreno G, Callejo M, Barreira B, Morales-Cano D, Esquivel-Ruiz S, Moreno L, et al. miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries. J Physiol 2019;597:1185-97.
• 25. Yavuzer H, Ali C, Yeşilova A, Cengi M, Yavuzer S, Yaldıran AL. [The investigation of MiR-125a and MiR-155 levels in white coat hypertension and essential hypertension]. Okmeydanı Tıp Dergisi 2017 33:261-9. [Article in Turkish]
• 26. Klimczak D, Kuch M, Pilecki T, Żochowska D, Wirkowska A, Pączek L. Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension. J Am Soc Hypertens. 2017;11:831-41.e4.
• 27. Zeng J, Lei J, Wei Y, Zheng Z, Zhang W, Fu Y, et al. Molecular mechanisms in microRNA-mediated TRB3 gene and hypertension left ventricular hypertrophy. Exp Ther Med 2017;13:1907-11.
• 28. Li F, Shi W, Wan Y, Wang Q, Feng W, Yan X. Prediction of target genes for miR-140-5p in pulmonary arterial hypertension using bioinformatics methods. FEBS Open Bio 2017;7:1880-90.
• 29. Zhang X, Wang X, Wu J, Peng J, Deng X, Shen Y, et al. The diagnostic values of circulating miRNAs for hypertension and bioinformatics analysis. Biosci Rep 2018;38:BSR20180525.
• 30. Biró O, Alasztics B, Molvarec A, Joó J, Nagy B, Rigó J Jr. Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension. Pregnancy Hypertens 2017;10:207-12.
• 31. Li Q, Qian Z, Wang L. Pri-microRNA-124 rs531564 polymorphism minor allele increases the risk of pulmonary artery hypertension by abnormally enhancing proliferation of pulmonary artery smooth muscle cells. Int J Chron Obstruct Pulmon Dis 2017;12:1351-61.
• 32. Zeng Z, Yao J, Li Y, Xue Y, Zou Y, Shu Z, et al. Anti-apoptosis endothelial cell-secreted microRNA-195-5p promotes pulmonary arterial smooth muscle cell proliferation and migration in pulmonary arterial hypertension. J Cell Biochem 2018;119:2144-55.
• 33. Li Y, Ren W, Wang X, Yu X, Cui L, Li X, et al. MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension. Biomed Pharmacother 2019;109:1740-9.